Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Swift who wrote (2287)	4/13/1999 5:11:00 PM
From: Don Miller	Read Replies (1) of 10280

FYI, JNJ looking to fill 2000 pipeline by "in-licensing and acquisitions"- RESEARCH ALERT-Johnson/Johnson target price upped NEW YORK,, April 13 (Reuters) - Warburg Dillon Read LLC said Tuesday it is raising its target price for Johnson & Johnson to $120 per share from $100 per share and reiterating its buy rating on the healthcare giant. -- The firm says in a report it sees an acceleration in top line growth to 12 to 13 percent for the year versus the 4.5 percent growth posted in 1998. The drivers for this improved growth outlook include a rebound in sales growth at the Professional Division and continued strong pharmaceuticals growth. -- Says while J&J's pipeline has only three new compounds slotted for launch through 2000, it expects the company to fill the gap through in-licensing and acquisitions. ((Laney Salisbury Health Desk 212-859-1700)) REUTERS Copyright 1998 Reuters Limited. All rights reserved. Republication and redissemination of the contents of this screen are expressly prohibited without Reuters' prior written consent.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next